PROs in Chronic Cervical Pain Patients With Accompanying Upper Limb Radiating Pain Treated With Pregabalin

Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT02868359
Collaborator
(none)
369
33
12.7
11.2
0.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effect of pregabalin on patient reported outcomes compared with conventional analgesic care in chronic cervical pain patients with accompanying upper limb radiating pain (neuropathic component) treated in primary care settings under routine clinical practice.

Condition or Disease Intervention/Treatment Phase
  • Other: No Intervention

Detailed Description

Rational and background:

Cervical pain with upper limb radiating pain(neuropathic component), such as cervical spondylosis radiculopathy or cervical spondylotic myelopathy, is one of the typical and common neuropathic pain. However, in Japan, large number of those patients are treated with NSAIDs without adequately assessing the cause of pain, despite that α2δ ligand, SNRI (Serotonin and Norepinephrine Reuptake Inhibitors ), and TCA (Tricyclic Antidepressants) are recommended in the clinical guidelines for neuropathic pain. Therefore, treatment satisfaction of these patients is low. This is currently a major issue in treatment for cervical pain with neuropathic component in Japan. In fact, our previous study which assessed the effect of pregabalin in low back pain patients with radiculopathy suggested that the selection of appropriate analgesics according to the cause of pain improved pain related sleep interference, pain and function. However, there are a few reports with regard to effect of pregabalin in cervical pain patients with neuropathic component. Therefore, we propose to conduct an observational study in order to assess the effects of pregabalin in cervical radiculopathy, when added to routine clinical care. The present study can encourage an understanding of the necessary of assessing cause of the pain, and treating with appropriate analgesics.

Research objectives :

To evaluate the effect of pregabalin comparing with the conventional analgesic care in chronic cervical pain patients with accompanying upper limb radiating pain(neuropathic component) treated in primary care settings under routine clinical practice.

Study design:

This is an 8-week, multicenter prospective non-interventional observational study. Subjects who have chronic cervical radiating pain patients with accompanying upper limb radiating pain (with a neuropathic component) and meet all other entry criteria are enrolled at baseline in the duration of study. Study arms are pregabalin with or without usual care vs. usual care (mono/combo therapy). The usual care are assumed NSAIDs, Antidepressants, weak opioids, acetaminophen etc.

The analgesic treatment is determined by the clinical judgment of the physician in charge of patient management. This therapeutic choice is not related to the decision to take part in the study. All enrolled subjects will be received with analgesic treatment. The study requires 3 visits at least, baseline/enrollment visit, Week 4 visit and Week 8 visit (or discontinuation).

Study Design

Study Type:
Observational
Actual Enrollment :
369 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
PATIENT-REPORTED-OUTCOMES IN CHRONIC CERVICAL PAIN PATIENTS WITH ACCOMPANYING UPPER LIMB RADIATING PAIN (NEUROPATHIC COMPONENT) TREATED WITH PREGABALIN IN PRIMARY CARE SETTINGS
Actual Study Start Date :
Oct 1, 2016
Actual Primary Completion Date :
Oct 24, 2017
Actual Study Completion Date :
Oct 24, 2017

Arms and Interventions

Arm Intervention/Treatment
Pregabalin / Other analgesics

Patients will be treated for 8 weeks with pregabalin in primary care: no intervention

Other: No Intervention
The study is observational.

Other analgesics

Patients will be treated for 8 weeks with other analgesics in usual care: no intervention

Other: No Intervention
The study is observational.

Outcome Measures

Primary Outcome Measures

  1. Change From Baseline at 8 weeks in Pain Related Sleep Interference Scale (PRSIS - Past Week Recall) [Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)]

    The Pain Related Sleep Interference Scale (past week recall) consists of an 11-point numeric rating scale (NRS) ranging from 0 (pain did not interfere with sleep) to 10 (pain completely interfered with sleep). Subjects are to describe how their pain has interfered with their sleep during the past week by choosing the appropriate number between 0 and 10.

Secondary Outcome Measures

  1. Change From Baseline in Neck Disability Index (NDI) [Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)]

    The Neck Disability Index (NDI) is an index of how well patients with cervical pain are able to function with regard to daily activities. The score for the index ranges from 0 to 50 with a lower score indicating better function. In the event that a patient has used rescue medication within 12 hours of the clinic visit, the patient should respond to the questions based on their functional ability in the 24 hour period just preceding the use of rescue medication.

  2. Change From Baseline in Pain Numeric Rating Scale (Pain NRS - past week recall) [Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)]

    The Pain NRS (past week recall) consists of an 11-point numeric rating scale (NRS) ranging from 0 (no pain) to 10 (worst possible pain). Subjects are asked to describe their average pain during the past week by choosing the appropriate number between 0 and 10.

  3. Change From Baseline in Euro Qol- 5 Dimensions -5 Level (EQ-5D-5L)-QOL-Score- [Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)]

    The EQ-5D-5L is a copyrighted, subject-completed questionnaire designed to assess health-related quality of life in terms of a single index value or utility score. There are two components to the EQ-5D-5L: A Health State Profile and a Visual Analogue Scale (VAS). Recent guidance suggests that the Health State Profile and VAS should be administered together. The Health State Profile is designed to record the subject's level of current health for five domains comprising a health profile: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Responses from the five domains are used to calculate a single utility index value.

  4. Change From Baseline in Euro Qol- 5 Dimensions -5 Level (EQ-5D-5L)-Visual Analogue Scale - [Baseline, Visit 2 (week 4), Final visit (week 8 or discontinuation)]

    The EQ-5D-5L is a copyrighted, subject-completed questionnaire designed to assess health-related quality of life in terms of a single index value or utility score. There are two components to the EQ-5D-5L: A Health State Profile and a Visual Analogue Scale (VAS). Recent guidance suggests that the Health State Profile and VAS should be administered together. The Visual Analogue Scale (VAS) is designed to rate the subject's current health state on a scale from 0 to 100 where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.

  5. Clinical Global Impression of Change (CGIC) [Final visit (week 8 or discontinuation)]

    The CGIC assessment includes one question (1-7 scale) inquiring about the subject's improvement considering their current disease state.

  6. Patient Global Impression of Change (PGIC) [Final visit (week 8 or discontinuation)]

    The PGIC is a subject-rated instrument that measures change in the subject's overall status on a 7-point scale. Scores range from 1 (very much improved) to 7 (very much worse).

  7. Work Productivity and Activity Impairment Questionnaire: (WPAI: GH) [Final visit (week 8 or discontinuation)]

    The WPAI: GH is a self-administered questionnaire that measures the effect of general health and symptom severity on work productivity and regular activities. Unlike general health or disease-specific measures, the WPAI:GH assesses function-related endpoints to allow a measure of the economic impact of relative differences in either the safety or efficacy of therapeutic endpoints. In this study, the WPAI: GH will measure the effect of the patient's chronic cervical pain with accompanying upper limb pain (neuropathic component) on work productivity and regular activities.

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Subject who received the enough study information and signed informed consent form.

Subject who had chronic pain with accompanying radiating pain to the superior limb beyond the elbow.

Subject is male or female patient ≧20 years old. Subject who reported neck pain with accompanying radiating pain to superior limb (12 weeks or greater in duration at Visit 0).

Subject who is refractory to previous analgesics for 12 weeks and more. Subject who is able and willing to complete all study related assessment tools and complied with scheduled clinic visits and clinical study procedures.

Subject whose pain NRS ≧5 and PRSIS ≧1 at baseline (based on recall over the past week).

Exclusion Criteria:

Subject who, in the opinion of the investigator, was not likely to complete the trial for whatever reason.

Subject who was treated with Pregabalin within the past 12 weeks (on baseline). Subject who has been regularly treated cervical pain with nerve blocks (such as stellate ganglion block, epidural block, radicular block and trigger point injection etc.).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Satoh Orthopaedic Clinic Ichikawa Chiba Japan 272-0021
2 Shiraishi Orthopaedic Clinic Ichikawa Chiba Japan 272-0138
3 Chihaya Hospital Fukuoka-shi Fukuoka Japan 813-8501
4 Clinic for Sports Medicine and Nutrition Fukuokashi Fukuoka Japan 810-0022
5 Seiwa Orthopedics Surgery Internal Medicine Fukuokashi Fukuoka Japan 812-0041
6 Kiheikai Yoh Orthopedic Clinic Fukuokashi Fukuoka Japan 812-0046
7 Fukuoka Mirai Hospital Higashi-ku,Fukuoka Fukuoka Japan 813-0017
8 Shin Komonji Hospital Kitakyusyu-shi Fukuoka Japan 800-0057
9 Takasaki Pain Clinic Takasaki-shi Gunma Japan 370-0035
10 Miyanomori Memorial Hospital Sapporoshi Hokkaido Japan 064-8570
11 Oomuro Orthopedic Clinic Himeji-shi Hyogo Japan 670-0976
12 Oonishi Medical Clinic Kako-gun Hyogo Japan 675-1115
13 Watanabe Orthopaedic Clinic Kobe Hyogo Japan 657-0824
14 Fujisawa Shonandai Hospital Fujisawa-shi Kanagawa Japan 252-0802
15 Ando Orthopaedics Hospital Kawasakishi Kanagawa Japan 213-0001
16 General Sagami Kosei Hospital Sagamiharashi Kanagawa Japan 252-5225
17 Arai Orthopaedic Clinic Saitama Kanagawa Japan 356-0004
18 Saitoh Orthopedic Sports Clinic Yamato-shi Kanagawa Japan 242-0024
19 Ageo Medical Clinic Ageo Saitama Japan 362-0021
20 Nakaicho Clinic Adachi Tokyo Japan 120-0033
21 Kyobashi Orthopaedic Clinic Chuo Tokyo Japan 104-0031
22 Morishima Clinic Edogawa Tokyo Japan 133-0057
23 Shinkoiwa Ekimae Sogo Clinic Katsushika Tokyo Japan 124-0024
24 Meguro Seikeigeka Naika Meguro Tokyo Japan 152-0002
25 Meguro Yuai Clinic Meguro Tokyo Japan 153-0065
26 Takemoto Orthopaedic Clinic Ohta Tokyo Japan 145-0066
27 Ohimachi Orthopaedic Clinic Shinagawa Tokyo Japan 140-0014
28 Shinjuku Research Park Clinic Shinnzyuku Tokyo Japan 169-0073
29 Kouenji Orthopedic Clinic Suginami Tokyo Japan 166-0003
30 Daido Hospital Toshima Tokyo Japan 171-0033
31 Fukushima Daiichi Hospital Fukusima Japan 960-8251
32 Saga-ken Medical Center Koseikan Saga Japan 840-8571
33 Tokyo Rheumatism Pain Clinic Tokyo Japan 104-0031

Sponsors and Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Investigators

  • Study Director: Pfizer CT.gov Call Center, Pfizer

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
ClinicalTrials.gov Identifier:
NCT02868359
Other Study ID Numbers:
  • A0081354
First Posted:
Aug 16, 2016
Last Update Posted:
Jan 20, 2021
Last Verified:
Jan 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2021